ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2017年09月13日 13時30分
Source:
Eisai
エーザイ、ウイルス・菌を除去 抗菌作用が1週間続く持続型抗菌成分Etak(R)配合「イータック(R)抗菌化スプレーα 」新発売
東京, 2017年09月13日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、ウイルス・菌を除去し、抗菌作用が1週間持続する、持続型抗菌成分Etak(R)配合の「イータック(R)抗菌化スプレーα(アルファ)」(雑貨)を9月19日(火)に新発売します。
本製品の主成分であるEtak(R)は、広島大学大学院 医歯薬保健学研究科 二川浩樹教授により開発された、持続型抗菌成分です。スプレーした箇所に、Etak(R)の接着成分が化学結合して抗菌成分が固定化されることで抗菌作用が1週間持続します。
家の中にはドアノブ、手すり、机、床、おもちゃなど、手で触ることによってウイルス・菌が拡散しやすい場所がたくさんあります。本製品は、そのようなウイルス・菌を寄せ付けたくないと願う生活者の皆様のニーズにお応えする製品です。ウイルス・菌を除去し、抗菌作用が1週間持続する「イータック抗菌化スプレーα」は、家の中のウイルス・菌対策の新習慣を提案します。また、無香料・無着色のノンアルコールタイプで、気になるところに幅広くお使いいただけます。
当社では持続型抗菌成分Etak(R)を配合した製品として、マスク着用前にスプレーするだけで、ウイルス・菌のマスクへの付着を24時間防ぐ、アルコールタイプのマスク用スプレー「イータック(R)抗菌化スプレー」も発売しています。
当社は、今後も生活者の皆様の多様なニーズにお応えする製品をお届けし、ベネフィット向上にさらに貢献してまいります。
「イータック(R)抗菌化スプレーα」の詳細については製品サイトをご覧ください。
http://www.eisai.jp/health-care/products/etak2/
本リリースの詳細は下記をご参照ください。
http://www.eisai.co.jp/news/news201748.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
Mar 27, 2026 20:14 JST
Hitachi and MUFG Bank expand NextGen model to finance vehicles and charging infrastructure for decarbonized mobility
Mar 27, 2026 19:44 JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Mar 27, 2026 18:19 JST
New "L00 Series" Train for the Seibu Railway's Yamaguchi Line Begins Commercial Operation
Mar 27, 2026 16:51 JST
Fujitsu develops high-sensitivity, high-resolution infrared sensor to expand monitoring capabilities in defense and disaster prevention
Mar 27, 2026 14:07 JST
Sharp Develops Long-Range Video Monitoring Technology
Mar 26, 2026 22:39 JST
OKI and Hitachi Agree to Integrate Businesses Related to Automated Teller Machines (ATMs) and Other Automated Equipment
Mar 26, 2026 22:10 JST
Hitachi Rail to manufacture rolling stock for Seibu Railway"s new Fine Dining Train
Mar 26, 2026 15:13 JST
Royal Healthcare in Singapore provides NEC's "FonesVisuas Test" for Disease Risk Prediction
Mar 26, 2026 11:21 JST
MHI-AP Awarded Boiler Retrofit Contract for Waste-to-Energy Facility in Singapore
Mar 26, 2026 11:07 JST
Sumitomo Heavy Industries and NEC to develop system capable of identifying and reporting near-miss incidents
Mar 25, 2026 14:27 JST
NEC Orchestrating Future Fund Invests in U.S.-based AGI7, Provider of "Alpha Vision" Platform for Autonomous Operations of AI Agents in Physical Spaces
Mar 25, 2026 13:17 JST
Fujitsu and The University of Osaka develop new technologies for chemical material energy calculations on early-FTQC quantum computers
Mar 25, 2026 10:58 JST
HIES introduces plant-based lubricant that reduces air compressor lifecycle CO(2) emissions by 40%
Mar 24, 2026 18:07 JST
Fujitsu and Umios conduct joint pilot project for electronic traceability system to visualize seafood distribution
Mar 24, 2026 14:01 JST
Fujitsu-developed traffic simulation system utilized in Maebashi City's public transportation planning
Mar 23, 2026 14:24 JST
Hitachi Receives the 2026 Catalyst Award, a Global Recognition for Building an Inclusive Organization
Mar 23, 2026 11:49 JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
Mar 23, 2026 11:19 JST
Honda to Expand Motorcycle Production Capacity in India by Adding New Motorcycle Production Line to its Second Plant
Mar 19, 2026 18:32 JST
Honda WN7 Electric Motorcycle Wins Gold Award at iF DESIGN AWARD 2026
Mar 19, 2026 18:16 JST
More Latest Release >>
Related Release
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
3/27/2026 8:14:00 PM JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
3/27/2026 6:19:00 PM JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
3/23/2026 11:19:00 AM JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
3/19/2026 10:54:00 AM JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
3/17/2026 7:49:00 PM JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
3/12/2026 5:21:00 PM JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
3/11/2026 12:07:00 PM JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
3/2/2026 9:49:00 AM JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
2/16/2026 2:03:00 PM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
2/10/2026 1:34:00 PM JST
More Press release >>